Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Pyxis Oncology, Inc. (PYXS) was the subject of Schedule 13G reports in which OrbiMed Advisors LLC reported beneficial ownership of 4,013,720 shares (3.4%), with shared voting and dispositive power, and OrbiMed Capital LLC reported 4,348,197 shares (3.6%), with sole voting and dispositive power.
The two reporting persons stated that they hold 7.0% of the common stock on behalf of other persons entitled to receive dividends or sale proceeds.
Key Figures
Beneficial ownership, OrbiMed Advisors LLC:4,013,720 sharesBeneficial ownership, OrbiMed Capital LLC:4,348,197 sharesShares held on behalf of other persons:7.0% of the common stock
3 metrics
Beneficial ownership, OrbiMed Advisors LLC4,013,720 shares3.4% of the class
Beneficial ownership, OrbiMed Capital LLC4,348,197 shares3.6% of the class
Shares held on behalf of other persons7.0% of the common stockOther persons have rights to dividends or proceeds from sales of these securities
Key Terms
beneficial ownership, dispositive power
2 terms
beneficial ownershipregulatory
"Amount beneficially owned: OrbiMed Advisors LLC"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
dispositive powerregulatory
"Shared dispositive power 4,013,720"
Dispositive power is the authority to decide the final outcome of an asset, legal claim, contract, or corporate action — in effect the power to dispose of or resolve something. For investors it matters because whoever holds that authority can determine who gets paid, who controls an asset or vote, and how risks and returns are allocated; think of it like holding the key that lets you lock in the winner or loser in a deal.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How many PYXS shares did OrbiMed Advisors and OrbiMed Capital report?
OrbiMed Advisors LLC reported beneficial ownership of 4,013,720 shares, or 3.4%, and OrbiMed Capital LLC reported 4,348,197 shares, or 3.6%.
Who exercises voting and investment power over the reported PYXS shares?
OrbiMed Advisors LLC and OrbiMed Capital LLC exercise voting and investment power through a management committee comprising Carl L. Gordon, W. Carter Neild and Geoffrey C. Hsu. Each committee member disclaims beneficial ownership of the reported shares.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
Pyxis Oncology, Inc.
(Name of Issuer)
Common Stock, par value $0.001
(Title of Class of Securities)
747324101
(CUSIP Number)
09/30/2026
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)
schemaVersion:
SCHEDULE 13G
CUSIP Number(s):
747324101
1
Names of Reporting Persons
OrbiMed Advisors LLC
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
4,013,720.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
4,013,720.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
4,013,720.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
3.4 %
12
Type of Reporting Person (See Instructions)
IA
SCHEDULE 13G
CUSIP Number(s):
747324101
1
Names of Reporting Persons
OrbiMed Capital LLC
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
4,348,197.00
6
Shared Voting Power
0.00
7
Sole Dispositive Power
4,348,197.00
8
Shared Dispositive Power
0.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
4,348,197.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
3.6 %
12
Type of Reporting Person (See Instructions)
IA
SCHEDULE 13G
Item 1.
(a)
Name of issuer:
Pyxis Oncology, Inc.
(b)
Address of issuer's principal executive offices:
321 Harrison Avenue Boston, MA, 02118
Item 2.
(a)
Name of person filing:
OrbiMed Advisors LLC
OrbiMed Capital LLC
(b)
Address or principal business office or, if none, residence:
601 Lexington Avenue, 54th Floor
New York, NY 10022
(c)
Citizenship:
Please refer to Item 4 on each cover sheet for each filing person.
(d)
Title of class of securities:
Common Stock, par value $0.001
(e)
CUSIP Number(s):
747324101
Item 3.
If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)
An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)
An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)
A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:
(k)
Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.
Ownership
(a)
Amount beneficially owned:
OrbiMed Advisors LLC: 4,013,720
OrbiMed Capital LLC: 4,348,197
(b)
Percent of class:
OrbiMed Advisors LLC: 3.4%
OrbiMed Capital LLC: 3.6%
(c)
Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote:
OrbiMed Advisors LLC: 0
OrbiMed Capital LLC: 4,348,197
(ii) Shared power to vote or to direct the vote:
OrbiMed Advisors LLC: 4,013,720
OrbiMed Capital LLC: 0
(iii) Sole power to dispose or to direct the disposition of:
OrbiMed Advisors LLC: 0
OrbiMed Capital LLC: 4,348,197
(iv) Shared power to dispose or to direct the disposition of:
OrbiMed Advisors LLC: 4,013,720
OrbiMed Capital LLC: 0
Item 5.
Ownership of 5 Percent or Less of a Class.
Not Applicable
Item 6.
Ownership of more than 5 Percent on Behalf of Another Person.
If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.
The Reporting Persons hold 7.0% of the shares of Common Stock in the aggregate on behalf of other persons who have the right to receive or the power to direct the receipt of dividends from, or proceeds from the sale of, such securities. OrbiMed Advisors LLC and OrbiMed Capital LLC exercise investment and voting power over the shares of Common Stock through a management committee comprised of Carl L. Gordon, W. Carter Neild, and Geoffrey C. Hsu, each of whom disclaims beneficial ownership of the shares of Common Stock reported herein.
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
Not Applicable
Item 8.
Identification and Classification of Members of the Group.
Not Applicable
Item 9.
Notice of Dissolution of Group.
Not Applicable
Item 10.
Certifications:
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.